<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; commercial</title>
	<atom:link href="http://www.tapanray.in/tag/commercial/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Exploiting India&#8217;s Weakness For Monopolistic Commercial Gain?</title>
		<link>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exploiting-indias-weakness-for-monopolistic-commercial-gain</link>
		<comments>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/#comments</comments>
		<pubDate>Mon, 08 May 2023 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10776</guid>
		<description><![CDATA[Public access to healthcare in India is a complex issue with several challenges. While India has been making progress over the years in improving healthcare access and reducing the burden of disease, there are still significant disparities in healthcare access &#8230; <a href="http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Sales Post Covid-19 Lockdown</title>
		<link>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-post-covid-19-lockdown</link>
		<comments>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/#comments</comments>
		<pubDate>Mon, 04 May 2020 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[customer-centricity]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[habit]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[oldest]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[post Covid-19]]></category>
		<category><![CDATA[preferences]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[years]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10054</guid>
		<description><![CDATA[Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer&#8217;s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global &#8230; <a href="http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Any Threat To Current Commercial Model Of ‘Gene Therapy’?</title>
		<link>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=any-threat-to-current-commercial-model-of-gene-therapy</link>
		<comments>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/#comments</comments>
		<pubDate>Mon, 30 Dec 2019 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CAR-T]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genetic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9833</guid>
		<description><![CDATA[Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 &#160; One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers &#8230; <a href="http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping Rich Harvest With Orphan Drugs</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-orphan-drugs</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/#comments</comments>
		<pubDate>Mon, 21 Oct 2019 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[health for all]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[quid pro quo]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich harvest]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9752</guid>
		<description><![CDATA[A set of perplexing questions on the drug industry has been haunting many, since long. One such area is intimately associated with the core purpose of this business, as enunciated by each company, often publicly. Just to give a feel &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India A Success Story With Biosimilar Drugs?</title>
		<link>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-a-success-story-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 25 Feb 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9422</guid>
		<description><![CDATA[How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse &#8211; but the initiative is not a current one. This journey commenced decades ago &#8230; <a href="http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Transparency in Drug Trial Data: Thwarted by Lobbyists or Embroiled in Controversy?</title>
		<link>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy</link>
		<comments>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/#comments</comments>
		<pubDate>Mon, 05 Aug 2013 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[Arguments]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[controversy]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[embroiled]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hardcore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[Jikei]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mobilizing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[poignant]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[thwarted]]></category>
		<category><![CDATA[thwarting]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[University]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3274</guid>
		<description><![CDATA[Based on a leaked letter from overseas pharma industry bodies, a leading international daily in late July 2013 reported: “Big pharma mobilizing patients in battle over drugs trials data.” Some experts consider it as a poignant, if not a bizarre &#8230; <a href="http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing in India: 10 Chain Events to Catalyze a Paradigm Shift</title>
		<link>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift</link>
		<comments>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/#comments</comments>
		<pubDate>Mon, 17 Jun 2013 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alibaba]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[composite]]></category>
		<category><![CDATA[Cosmetic]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[differentiated]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[faster]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[Heralding]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[ICICI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Lombard]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mediclaim]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of pharma]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmacy-economics]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[remedies]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transition]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2454</guid>
		<description><![CDATA[In the matured markets of the world pharmaceutical marketing is quite different in many respect as compared to India. Besides doctors, different sets of customer groups like, healthcare providers, patient advocacy groups, pharmacy benefit managers, clinical assessment authorities play various &#8230; <a href="http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs -A raging scientific debate with mounting global commercial interest</title>
		<link>http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/#comments</comments>
		<pubDate>Wed, 04 Mar 2009 13:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[mounting]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scientific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=953</guid>
		<description><![CDATA[On December 11, 2008, Reuters reported that two days after Merck &#38; Co. announced a major push into generic versions of biotechnology medicines, Eli Lilly &#38; Co. signaled similar aspirations. This report raised many eyebrows in the global pharmaceutical industry, &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-a-raging-scientific-debate-with-mounting-global-commercial-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
